Signature Blue_CRC was generated based on 3 training colorectal cancer cohorts and validated in another 20 independent cancer cohorts (n = 6,067). Cox regression analysis showed that this signature well predicted recurrence survival in almost all of the cohorts when either all stages of cancers (Fig.1) or stage 2&3 cancers (Fig.2) were tested. The prediction power of this signature in stage 2&3 cancers was also confirmed in Kaplan-Meier analysis (Fig.3).
Embedded Files
Fig. 1 Associations of Blue_CRC score with survival in cancers at all stages. The hazard ratio (HR) was shown in forest plot. Twenty three independent cancer cohorts (n = 6,067) were analyzed. In some of the cohorts, tumors are all or mainly at stage 2 & 3. The overall effect was calculated through a random-effects (RE) model.
Fig. 1 Associations of Blue_CRC score with survival in cancers at all stages. The hazard ratio (HR) was shown in forest plot. Twenty three independent cancer cohorts (n = 6,067) were analyzed. In some of the cohorts, tumors are all or mainly at stage 2 & 3. The overall effect was calculated through a random-effects (RE) model.
Fig. 2 Associations of Blue_CRC score with survival in stage 2&3 cancers. Only stage 2&3 cancers were analyzed here. The hazard ratio (HR) was shown in forest plot.
Fig. 2 Associations of Blue_CRC score with survival in stage 2&3 cancers. Only stage 2&3 cancers were analyzed here. The hazard ratio (HR) was shown in forest plot.
Fig. 3 Kaplan-Meier analysis of the association of BlueCRC score with recurrence risk in stage 2&3 cancers. Only stage 2&3 cancers were analyzed here. Each Kaplan-Meier plot represents an analysis result for one cohort.
Fig. 3 Kaplan-Meier analysis of the association of BlueCRC score with recurrence risk in stage 2&3 cancers. Only stage 2&3 cancers were analyzed here. Each Kaplan-Meier plot represents an analysis result for one cohort.
Page updated
Google Sites
Report abuse